Sermonix Pharmaceuticals
Columbus, US · Founded 2014 · Delaware corporation
Sermonix Pharmaceuticals is a privately held biotechnology company developing female-specific oncology products, with a lead investigational drug, lasofoxifene, being studied for breast and ovarian cancer. Its ELAINE study evaluates lasofoxifene versus fulvestrant in women with ER+/HER2- metastatic breast cancer carrying an ESR1 mutation.
Founders & leadership
Sermonix Pharmaceuticals was founded in 2014 by David Portman.
DP
David PortmanFounder
MP
Miriam PortmanExecutive
Reported raises · per SEC filings
Form D private placements$42.8M disclosed across 3 rounds · 2015–2021
▶$40.2MraisedNov 2021 · 9 investors · PharmaceuticalsRule 506(b)
▶$40.2MraisedNov 2021 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Anthony WildExecutive Officer, Director
- Miriam PortmanExecutive Officer, Promoter
- Elizabeth AttiasExecutive Officer
- Michael FriedmanDirector
- Simon JenkinsExecutive Officer
- Elizabeth GarnerDirector
- David PortmanExecutive Officer, Director, Promoter
- Richard De SchutterDirector
- Barry KommExecutive Officer
- Thomas PfistererDirector
- Paul PlourdeExecutive Officer
- Offering amount
- $40.2M
- Amount sold
- $40.2M
- Sales commissions
- $2.2M
- Placement agents
- LIFESCI CAPITAL
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedJul 2016 · 2 investors · PharmaceuticalsRule 506(b)
▶$1.6MraisedJul 2016 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Miriam PortmanExecutive Officer, Director
- David PortmanExecutive Officer, Director
- Patrick WieselDirector
- Offering amount
- $2.5M
- Amount sold
- $1.6M
- Minimum investment
- $25K
- First sale
- Jul 2016
- Incorporated
- Limited Liability Company, Ohio, 2014
- Federal exemptions
- 06b
▶$1MraisedOct 2015 · 17 investors · PharmaceuticalsRule 506(b)
▶$1MraisedOct 2015 · 17 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Miriam PortmanExecutive Officer
- David PortmanExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $1M
- Minimum investment
- $50K
- First sale
- Sep 2015
- Incorporated
- Limited Liability Company, Ohio, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Sermonix Pharmaceuticals do?
- Sermonix Pharmaceuticals is a privately held biotechnology company developing female-specific oncology products, with a lead investigational drug, lasofoxifene, being studied for breast and ovarian cancer. Its ELAINE study evaluates lasofoxifene versus fulvestrant in women with ER+/HER2- metastatic breast cancer carrying an ESR1 mutation.
- Who founded Sermonix Pharmaceuticals?
- Sermonix Pharmaceuticals was founded by David Portman in 2014.
- How much funding has Sermonix Pharmaceuticals raised?
- Sermonix Pharmaceuticals has disclosed $42.8M raised across 3 rounds.
- Where is Sermonix Pharmaceuticals headquartered?
- Sermonix Pharmaceuticals is headquartered in Columbus, US.